Opendata, web and dolomites

EuroNeurotrophin SIGNED

A European training network for the discovery of neurotrophins small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EuroNeurotrophin project word cloud

Explore the words cloud of the EuroNeurotrophin project. It provides you a very rough idea of what is the project "EuroNeurotrophin" about.

comprehend    societies    penetration    pharmacokinetic    neurotrophins    stage    skilled    neurogenesis    mnd    molecular    candidate    small    neurotrophin    first    complementary    actions    network    patented    tackle    ms    12    motivated    biological    limitation    therapies    pd    exists    profiles    render    private    prohibitive    drugs    of    tissue    neuroprotection    forth    enriched    discovery    nd    skills    preclinical    possess    deep    als    mimetics    collaborations    companies    point    single    translate    groups    pathogenesis    specialists    collectively    interrogate    neurodegenerative    consists    market    nhrf    fail    academic    therapeutic    training    14    clinical    molecule    seminal    survival    treatments    doctoral    ad    accelerate    conduct    probes    function    idea    poor    cure    successful    beneficiaries    neurons    expertise    diseases    emphasise    translation    collaborative    stability    worldwide    shown    builds    drug    euroneurotrophin    molecules    designed    demonstrated   

Project "EuroNeurotrophin" data sheet

The following table provides information about the project.

Coordinator
ETHNIKO IDRYMA EREVNON 

Organization address
address: VAS KONSTANTINOU 48
city: ATHINA
postcode: 11635
website: www.eie.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 3˙555˙758 €
 EC max contribution 3˙555˙758 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ETHNIKO IDRYMA EREVNON EL (ATHINA) coordinator 484˙773.00
2    AvantiCell Science Ltd UK (AYR) participant 546˙575.00
3    HITS GGMBH DE (HEIDELBERG) participant 498˙432.00
4    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) participant 484˙773.00
5    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 273˙287.00
6    UNIVERSITE DE CAEN NORMANDIE FR (CAEN CEDEX 5) participant 262˙875.00
7    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 258˙061.00
8    STICHTING VU NL (AMSTERDAM) participant 255˙374.00
9    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 249˙216.00
10    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 242˙386.00
11    ACCELOPMENT AG CH (ZUERICH) partner 0.00
12    Innovative Technologies in Biological Systems ES (Derio) partner 0.00
13    Novartis (Ελλάς) Α.Ε.Β.Ε. EL (Metamorphosis) partner 0.00
14    PANEPISTIMIO KRITIS EL (RETHIMNO) partner 0.00
15    Peakdale Molecular Limited UK (Chapel-en-le-Frith) partner 0.00
16    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) partner 0.00
17    Ventac A/S DK (Hoersholm) partner 0.00

Map

 Project objective

Neurodegenerative diseases (ND) like AD, PD, MS and ALS/MND are on the rise in developed societies worldwide. Currently, there exists no cure for any ND, and most of the available drugs fail to tackle ND pathogenesis. Preclinical studies point to the therapeutic potential of neurotrophins, which have been shown to control a number of aspects of survival, development and function of neurons. However, the poor pharmacokinetic properties of neurotrophins render their use as drugs prohibitive. The key idea behind this project is to address this limitation by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions. We are motivated by seminal (patented) results of beneficiaries NHRF and FORTH, who recently demonstrated promising effects of small neurotrophin mimetics in neuroprotection and neurogenesis. EuroNeurotrophin will be the first European consortium to study small molecule neurotrophin mimetics in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation. This approach requires highly skilled researchers that have a deep understanding of neurotrophins, comprehend all steps of drug discovery and development for ND, and possess the necessary skills to translate results into novel therapies. The network has been designed to address the need for the development of new ND treatments through the collaborative training of 14 early-stage researchers. It builds on previous successful collaborations enriched with key specialists, and consists of 12 leading European research groups and 6 private companies of complementary expertise covering all steps of drug discovery and development. Collectively we will (a) conduct a unique training programme that could not be achieved by doctoral training within a single academic institution and (b) accelerate the translation of identified drug candidate molecules into the market.

 Publications

year authors and title journal last update
List of publications.
2020 Athanasios Ziogas, Tomoki Maekawa, Johannes R. Wiessner, Thi Trang Le, David Sprott, Maria Troullinaki, Ales Neuwirth, Vasiliki Anastasopoulou, Sylvia Grossklaus, Kyoung-Jin Chung, Markus Sperandio, Triantafyllos Chavakis, George Hajishengallis, Vasileia Ismini Alexaki
DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1
published pages: 1214-1224, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900746
The Journal of Immunology 204/5 2020-03-11
2019 Canelif Yilmaz, Kanelina Karali, Georgia Fodelianaki, Achille Gravanis, Triantafyllos Chavakis, Ioannis Charalampopoulos, Vasileia Ismini Alexaki
Neurosteroids as regulators of neuroinflammation
published pages: 100788, ISSN: 0091-3022, DOI: 10.1016/j.yfrne.2019.100788
Frontiers in Neuroendocrinology 55 2020-03-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURONEUROTROPHIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EURONEUROTROPHIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

MOSAICS (2019)

Hearing Matters: European Industrial Doctorate to train experts in auditory implants for minimised outcome spread and maximized participation in society

Read More  

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

I-DireCT (2019)

Immune DIREcted and Cancer-selective immunoTherapy

Read More